Apolipoprotein C-III: From Pathophysiology to Pharmacology
© 2015 Elsevier Ltd. All rights reserved. Apolipoprotein C-III (apoC-III) has a critical role in the metabolism of triglyceride (TG)-rich lipoproteins (TRLs). Animal models lacking the APOC3 gene exhibit reduced plasma TG levels, whereas the overexpression of APOC3 leads to increased TG levels. In h...
| Main Authors: | , , , |
|---|---|
| Format: | Journal Article |
| Published: |
2015
|
| Online Access: | http://hdl.handle.net/20.500.11937/56381 |
| _version_ | 1848759860871561216 |
|---|---|
| author | Norata, Giuseppe Tsimikas, S. Pirillo, A. Catapano, A. |
| author_facet | Norata, Giuseppe Tsimikas, S. Pirillo, A. Catapano, A. |
| author_sort | Norata, Giuseppe |
| building | Curtin Institutional Repository |
| collection | Online Access |
| description | © 2015 Elsevier Ltd. All rights reserved. Apolipoprotein C-III (apoC-III) has a critical role in the metabolism of triglyceride (TG)-rich lipoproteins (TRLs). Animal models lacking the APOC3 gene exhibit reduced plasma TG levels, whereas the overexpression of APOC3 leads to increased TG levels. In humans, loss-of-function mutations in APOC3 are associated with reduced plasma TG levels and reduced risk for ischemic vascular disease and coronary heart disease. Several hypolipidemic agents have been shown to reduce apoC-III, including fibrates and statins, and antisense technology aimed at inhibiting APOC3 mRNA to decrease the production of apoC-III is currently in Phase III of clinical development. Here, we review the pathophysiological role of apoC-III in TG metabolism and the evidence supporting this apolipoprotein as an emerging target for hypertriglyceridemia (HTG) and associated cardiovascular disorders. |
| first_indexed | 2025-11-14T10:06:36Z |
| format | Journal Article |
| id | curtin-20.500.11937-56381 |
| institution | Curtin University Malaysia |
| institution_category | Local University |
| last_indexed | 2025-11-14T10:06:36Z |
| publishDate | 2015 |
| recordtype | eprints |
| repository_type | Digital Repository |
| spelling | curtin-20.500.11937-563812017-09-13T16:09:54Z Apolipoprotein C-III: From Pathophysiology to Pharmacology Norata, Giuseppe Tsimikas, S. Pirillo, A. Catapano, A. © 2015 Elsevier Ltd. All rights reserved. Apolipoprotein C-III (apoC-III) has a critical role in the metabolism of triglyceride (TG)-rich lipoproteins (TRLs). Animal models lacking the APOC3 gene exhibit reduced plasma TG levels, whereas the overexpression of APOC3 leads to increased TG levels. In humans, loss-of-function mutations in APOC3 are associated with reduced plasma TG levels and reduced risk for ischemic vascular disease and coronary heart disease. Several hypolipidemic agents have been shown to reduce apoC-III, including fibrates and statins, and antisense technology aimed at inhibiting APOC3 mRNA to decrease the production of apoC-III is currently in Phase III of clinical development. Here, we review the pathophysiological role of apoC-III in TG metabolism and the evidence supporting this apolipoprotein as an emerging target for hypertriglyceridemia (HTG) and associated cardiovascular disorders. 2015 Journal Article http://hdl.handle.net/20.500.11937/56381 10.1016/j.tips.2015.07.001 restricted |
| spellingShingle | Norata, Giuseppe Tsimikas, S. Pirillo, A. Catapano, A. Apolipoprotein C-III: From Pathophysiology to Pharmacology |
| title | Apolipoprotein C-III: From Pathophysiology to Pharmacology |
| title_full | Apolipoprotein C-III: From Pathophysiology to Pharmacology |
| title_fullStr | Apolipoprotein C-III: From Pathophysiology to Pharmacology |
| title_full_unstemmed | Apolipoprotein C-III: From Pathophysiology to Pharmacology |
| title_short | Apolipoprotein C-III: From Pathophysiology to Pharmacology |
| title_sort | apolipoprotein c-iii: from pathophysiology to pharmacology |
| url | http://hdl.handle.net/20.500.11937/56381 |